In this unpredictable environment, Abbott has proved to be a consistent performer with its diversified business model and robust product portfolio.

This has translated to another dividend increase: an 8.5% boost to the quarterly dividend payouts for 2023, paying out at 51 cents per share.

This marks the 51^st consecutive year Abbott has raised its dividend payout, and it’s the 396^th consecutive quarterly dividend to be paid by Abbott since 1924. The company is a longtime member of the prestigious S&P 500 Dividend Aristocrats Index, comprising companies that have raised their dividend payout for at least 25 years.

Fueling this increase is strength across the company's diversified businesses and continued investment in its new product pipeline.

In 2022, Abbott's key growth-drivers expanded beyond the company's FreeStyle Libre system, MitraClip and Alinity to also include a number of minimally invasive cardiovascular technologies:

• Amplatzer Amulet Left Atrial Appendage Occluder, for people with atrial fibrillation
• Aveir single-chamber VR pacemaker system, treating slower-than-normal heart rates
• CardioMEMS, for heart failure
• Navitor Transcatheter Aortic Valve Implantation System, treating aortic stenosis
• TriClip Transcatheter Tricuspid Valve Repair System, for tricuspid valve regurgitation

Combined, these new cardiovascular technologies are growing 50% and are still "in the early innings of growth," said Abbott Chairman and CEO Robert Ford during the company's third quarter earnings call.

Fifty-one years of dividend increases demonstrates Abbott's longstanding commitment to delivering sustainable growth that fuels innovations as well as shareholder returns.

Learn more about Abbott's latest quarterly dividend increase.